Investigation of adsorption and release of diclofenac sodium by modified zeolites composites

Application of Artificial Neural Networks in Prediction of Diclofenac Sodium Release From Drug-Modified Zeolites Physical Mixtures and Antiedematous Activity Assessment

“…In addition, clinoptilolite crystals, having a nonfibrous morphology, contrary to erionite, are completely safe as regards the possible induction of mesothelioma . A minimum of surfactant desorption (less than 5%) from the zeolitic surfaces for all ZHBs in phosphate buffer at pH 6.8 (dissolution medium) was also determined . These results alongside with previous findings of nontoxic clinoptilolite effect make this mineral material a suitable applicant as excipient in pharmaceutical formulations.…”

“…In our previous study, it was shown that adsorption of DS by composites obtained by modification of NZs with HB was influenced by the surfactant amount present at the surface of the composites. Furthermore, the achieved maximal adsorption capacities were sometimes to low (∼45 mg/g) in terms of use the drug/modified zeolite composite as potential drug carriers.…”

“…In our previous studies, it was demonstrated that modification of NZ with cationic surfactant hexadecyltrimethylammonium bromide (HB) at different modification levels (10, 20, and 30 mmol/100 g, denoted as ZHB‐10, ZHB‐20, and ZHB‐30) resulted in an increase of the drug (diclofenac sodium) (DS) adsorbed amounts . Characterization of the composites before and after the drug adsorption was performed by determination of electrokinetic mobility, FTIR, and thermal analysis and the results indicated interactions between the drug and carriers.…”

“…In vitro drug release investigations revealed that prolonged DS release from the obtained drug‐modified zeolite composites during 8 h was achieved and that the maximum DS released amount (up to 30%) was obtained from DS/ZHB‐20 composite at surfactant/drug molar ratio (SDMR) (mmol HB/mmol DS ∼ 1.3). Furthermore, it was shown that prolonged drug release was also attained from the corresponding physical mixture of ZHB‐20 and DS at similar SDMR (∼1.4) and as well as from physical mixtures with decreasing SDMR (1.0, 0.7, and 0.4), that is, the drug content closer to a therapeutic dose …”

Surface modified natural zeolite as a carrier for sustained diclofenac release: A preliminary feasibility study

“…For this purpose, modification of the zeolite surface, according to external cation exchange capacity of the zeolite-rich rock, was performed, using cetylpyridinium chloride (CP-Cl) as cationic surfactants , while diclofenac sodium (DS) was used as the model drug since it has been already used in previous similar studies and since it possesses numerous pharmaceutical applications for both oral and topical route of administration [15][16][17]. In actual fact, DS is a non-steroidal antiinflammatory drug (NSAID) used to reduce inflammation and/or as an analgesic, reducing pain in certain conditions.…”